Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series

Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving tezepelumab treatment are presented.

Bibliografski detalji

Glavni autori:	Shigesato Inoue, MD, Hiroaki Ogata, MD, PhD, Yoichi Dotake, MD, Koichi Takagi, MD, PhD, Ayaka Shiota, MD, Yumiko Ishii, MD, PhD, Kentaro Tanaka, MD, PhD, Keiko Kan-o, MD, PhD, Hiromasa Inoue, MD, PhD
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-05-01
Serija:	Journal of Allergy and Clinical Immunology: Global
Teme:	Asthma control tezepelumab rhinosinusitis severe asthma nasal polyps
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2772829325000499
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!